High systemic inflammation response index level is associated with an increased risk of lower extremity deep venous thrombosis: a large retrospective study

References

• Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism: a review. JAMA. 2020;324(17):1–11. doi: 10.1001/jama.2020.17272.
   Web of Science ®Google Scholar
• Heit JA, Melton LJ, 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76(11):1102–1110. doi: 10.4065/76.11.1102.
   PubMed Web of Science ®Google Scholar
• Bjøri E, Johnsen HS, Hansen JB, et al. Hospitalization as a trigger for venous thromboembolism - Results from a population-based case-crossover study. Thromb Res. 2019;176:115–119. doi: 10.1016/j.thromres.2019.02.024.
   PubMed Web of Science ®Google Scholar
• Mehta KD, Siddappa Malleshappa SK, Patel S, et al. Trends of inpatient venous thromboembolism in United States before and after the surgeon general’s call to action. Am J Cardiol. 2019;124(6):960–965. doi: 10.1016/j.amjcard.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Neeman E, Liu V, Mishra P, et al. Trends and risk factors for venous thromboembolism among hospitalized medical patients. JAMA Netw Open. 2022;5(11):e2240373. doi: 10.1001/jamanetworkopen.
   PubMed Web of Science ®Google Scholar
• Hwang HG, Lee JH, Kim SA, et al. Incidence of venous thromboembolism: the 3rd Korean nationwide study. J Korean Med Sci. 2022;37(17):e130. doi: 10.3346/jkms.2022.37.e130.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lei J, Shao X, et al. Trends in hospitalization and in-hospital mortality from VTE, 2007 to 2016, in China. Chest. 2019;155(2):342–353. doi: 10.1016/j.chest.2018.10.040.
   PubMed Web of Science ®Google Scholar
• Izcovich A, Criniti JM, Popoff F, et al. Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Adv. 2020;4(7):1539–1553. doi: 10.1182/bloodadvances.2020001513.
   PubMed Web of Science ®Google Scholar
• Wang X, Ma Y, Hui X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2023;4(4):Cd010956. doi: 10.1002/14651858.CD010956.pub3.
   PubMedGoogle Scholar
• Broderick C, Watson L, Armon MP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev. 2021;1(1):Cd002783. doi: 10.1002/14651858.CD002783.pub5.
   PubMedGoogle Scholar
• Malhotra K, Bawa A, Goyal K, et al. Global impact of deep vein thrombosis awareness month: challenges and future recommendations. Eur Heart J. 2022;43(36):3379–3381. doi: 10.1093/eurheartj/ehac252.
   PubMed Web of Science ®Google Scholar
• ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580–1590. doi: 10.1111/jth.12698.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Neumann I, Ageno W, et al. American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi: 10.1182/bloodadvances.2020001830.
   PubMed Web of Science ®Google Scholar
• Neumann I, Izcovich A, Aguilar R, et al. ASH, ABHH, ACHO, grupo CAHT, grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, sociedad panameña de hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. Blood Adv. 2021;5(15):3032–3046. doi: 10.1182/bloodadvances.2021004267.
   PubMed Web of Science ®Google Scholar
• Tran HA, Gibbs H, Merriman E, et al. New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust. 2019;210(5):227–235. doi: 10.5694/mja2.50004.
   PubMed Web of Science ®Google Scholar
• Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. doi: 10.1016/j.chest.2021.07.055.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020;135(5):351–359. doi: 10.1182/blood.2019000919.
   PubMed Web of Science ®Google Scholar
• Ageno W, Bertù L, Bucherini E, et al. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. doi: 10.1136/bmj-2022-072623.
   PubMedGoogle Scholar
• Sidhu VS, Kelly TL, Pratt N, et al. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA. 2022;328(8):719–727. doi: 10.1001/jama.2022.13416.
   PubMed Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781–790. doi: 10.1016/j.chest.2021.09.037.
   PubMed Web of Science ®Google Scholar
• Becattini C, Pace U, Pirozzi F, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022;140(8):900–908. doi: 10.1182/blood.2022015796.
   PubMed Web of Science ®Google Scholar
• Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18(9):666–682. doi: 10.1038/s41569-021-00552-1.
   PubMed Web of Science ®Google Scholar
• Budnik I, Brill A. Immune factors in deep vein thrombosis initiation. Trends Immunol. 2018;39(8):610–623. doi: 10.1016/j.it.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Johnson TA, Duru N, et al. Fibrinolysis and inflammation in venous thrombus resolution. Front Immunol. 2019;10:1348. doi: 10.3389/fimmu.2019.01348.
   PubMed Web of Science ®Google Scholar
• Nicklas JM, Gordon AE, Henke PK. Resolution of deep venous thrombosis: proposed immune paradigms. Int J Mol Sci. 2020;21(6):2080. doi: 10.3390/ijms21062080.
   PubMed Web of Science ®Google Scholar
• Selvaggio S, Brugaletta G, Abate A, et al. Platelet‑to‑lymphocyte ratio, neutrophil‑to‑lymphocyte ratio and monocyte‑to‑HDL cholesterol ratio as helpful biomarkers for patients hospitalized for deep vein thrombosis. Int J Mol Med. 2023;51(6):52. doi: 10.3892/ijmm.2023.5255.
   PubMed Web of Science ®Google Scholar
• Mureșan AV, Hălmaciu I, Arbănași EM, et al. Prognostic nutritional index, controlling nutritional status (CONUT) score, and inflammatory biomarkers as predictors of deep vein thrombosis, acute pulmonary embolism, and mortality in COVID-19 patients. Diagnostics . 2022;12(11):2757. doi: 10.3390/diagnostics12112757.
   Web of Science ®Google Scholar
• Chen X, Ou Y, Wang Z, et al. Association between systemic immune-inflammation index and risk of lower extremity deep venous thrombosis in hospitalized patients: a 10-year retrospective analysis. Front Cardiovasc Med. 2023;10:1211294. doi: 10.3389/fcvm.2023.1211294.
   PubMed Web of Science ®Google Scholar
• Xue J, Ma D, Jiang J, et al. Diagnostic and prognostic value of immune/inflammation biomarkers for venous thromboembolism: is it reliable for clinical practice? J Inflamm Res. 2021;14:5059–5077. doi: 10.2147/JIR.S327014.
   PubMed Web of Science ®Google Scholar
• Zhao S, Dong S, Qin Y, et al. Inflammation index SIRI is associated with increased all-cause and cardiovascular mortality among patients with hypertension. Front Cardiovasc Med. 2022;9:1066219. doi: 10.3389/fcvm.2022.1066219.
   PubMed Web of Science ®Google Scholar
• Melinte RM, Arbănași EM, Blesneac A, et al. Inflammatory biomarkers as prognostic factors of acute deep vein thrombosis following the total knee arthroplasty. Medicina. 2022;58(10):1502. doi: 10.3390/medicina58101502.
   PubMedGoogle Scholar
• Wei Y, Wang T, Li G, et al. Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder. Front Psychiatry. 2022;13:941728. doi: 10.3389/fpsyt.2022.941728.
   PubMed Web of Science ®Google Scholar
• Zhou B, Meta C. Analysis group of China obesity task force. [predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population]. Zhonghua Liu Xing Bing Xue Za Zhi. 2002;23(1):5–10. doi: 10.3760/j.issn:0254-6450.2002.01.003.
   PubMedGoogle Scholar
• Glise Sandblad K, Rosengren A, Sörbo J, et al. Pulmonary embolism and deep vein thrombosis-comorbidities and temporary provoking factors in a register-based study of 1.48 million people. Res Pract Thromb Haemost. 2022;6(4):e12714. doi: 10.1002/rth2.12714.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao W, Zhao Z, et al. Leukocyte as an independent predictor of lower-extremity deep venous thrombosis in elderly patients with primary intracerebral hemorrhage. Front Neurol. 2022;13:899849. doi: 10.3389/fneur.2022.899849.
   PubMed Web of Science ®Google Scholar
• Liu X, Li T, Xu H, et al. Hyperglycemia may increase deep vein thrombosis in trauma patients with lower limb fracture. Front Cardiovasc Med. 2022;9:944506. doi: 10.3389/fcvm.2022.944506.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Modlitba A, Vasan SK, et al. Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million swedish and danish blood donors. Thromb Res. 2020;186:86–92. doi: 10.1016/j.thromres.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Edvardsen M, Hansen E, Hindberg K, et al. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood. 2021;138(22):2269–2277. doi: 10.1182/blood.2021011494.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Caraballo C, Trujillo-Santos J, et al. Clinical presentation and short- and long-term outcomes in patients with isolated distal deep vein thrombosis vs proximal deep vein thrombosis in the RIETE registry. JAMA Cardiol. 2022;7(8):857–865. doi: 10.1001/jamacardio.2022.1988.
   PubMed Web of Science ®Google Scholar
• Kuplay H, Erdoğan SB, Bastopcu M, et al. The neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio correlate with thrombus burden in deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2020;8(3):360–364. doi: 10.1016/j.jvsv.2019.05.007.
   PubMedGoogle Scholar
• Ma J, Du P, Qin J, et al. Incidence and risk factors predicting deep venous thrombosis of lower extremity following spinal fractures. Sci Rep. 2021;11(1):2441. doi: 10.1038/s41598-021-82147-x.
   PubMed Web of Science ®Google Scholar
• Choi J, Dekkers OM, Le Cessie S. A comparison of different methods to handle missing data in the context of propensity score analysis. Eur J Epidemiol. 2019;34(1):23–36. doi: 10.1007/s10654-018-0447-z.
   PubMed Web of Science ®Google Scholar
• Thompson WK, Xie M, White HR. Transformations of covariates for longitudinal data. Biostatistics. 2003;4(3):353–364. doi: 10.1093/biostatistics/4.3.353.
   PubMed Web of Science ®Google Scholar
• Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558–569. doi: 10.4097/kja.19087.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Song X, Ma J, et al. Association of inflammation indices with left atrial thrombus in patients with valvular atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):9. doi: 10.1186/s12872-023-03036-x.
   PubMed Web of Science ®Google Scholar
• Li J, He D, Yu J, et al. Dynamic status of SII and SIRI alters the risk of cardiovascular diseases: evidence from kailuan cohort study. J Inflamm Res. 2022;15:5945–5957. doi: 10.2147/JIR.S378309.
   PubMed Web of Science ®Google Scholar
• Jin Z, Wu Q, Chen S, et al. The associations of two novel inflammation indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: a ten-year follow-up study in 85,154 individuals. J Inflamm Res. 2021;14:131–140. doi: 10.2147/JIR.S283835.
   PubMed Web of Science ®Google Scholar
• Galloway J, Barrett K, Irving P, et al. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open. 2020;6(3):e001392. doi: 10.1136/rmdopen-2020-001392.
   PubMed Web of Science ®Google Scholar
• Yuan S, Bruzelius M, Damrauer SM, et al. Anti-inflammatory diet and venous thromboembolism: two prospective cohort studies. Nutr Metab Cardiovasc Dis. 2021;31(10):2831–2838. doi: 10.1016/j.numecd.2021.06.021.
   PubMed Web of Science ®Google Scholar
• Poredos P, Poredos P. Involvement of inflammation in venous thromboembolic disease: an update in the age of COVID-19. Semin Thromb Hemost. 2022;48(1):93–99. doi: 10.1055/s-0041-1732372.
   PubMedGoogle Scholar